Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

Neurology

Volumn 49, Issue 1, 1997, Pages 153-161

  Murman, D L ^a   Giordani, B ^b   Mellow, A M ^b   Johanns, J R ^c   Little, R J A ^c   Hariharan, M ^b   Foster, N L ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; EYE MOVEMENT; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MEMORY; PRIORITY JOURNAL;

EID: 0030753956     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.1.153     Document Type: Article

References (62)

1. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-624.
2. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
3. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-738.
4. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957;58:193-201.
5. Olney JW. Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW, McGeer PL, eds. Kainic acid as a tool in neurobiology. New York: Raven Press, 1978:1-15.
6. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature 1986; 321:519-522.
7. Choi DW, Koh J, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988;8:185-196.
8. 2+ prevents neurotoxicity. Brain Res 1992;598:196-202.
9. Foster AC, Gill R, Kemp JA, Woodruff GN. Systemic administration of MK-801 prevents N-methyl-D-aspartate-induced neuronal degeneration in rat brain. Neurosci Lett 1987;76: 307-311.
10. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 1995;36:186-195.
11. Harris JA, Biersner RJ, Edwards D, Bailey LW. Attention, learning, and personality during ketamine emergence: a pilot study. Anesth Analg 1975;54:169-172.
12. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 1985;5:70-77.
13. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209-1213.
14. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994;51:199-214.
15. Greenamyre JT, Penney JB, Young AB, D'Amato CJ, Hicks SP, Shoulson I. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science 1985;227:1496-1499.
16. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988;241:981-983.
17. Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990; 322:1293-1298.
18. Dure LS, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991;30:785-793.
19. Brandt JA, Bylsma FW. The dementia of Huntington's disease. In: Parks RW, Zee RF, Wilson RS, eds. Neuropsychology of Alzheimer's disease and other dementias. Oxford: Oxford University Press, 1993:265-282.
20. Boivin MJ, Giordani B, Berent S, et al. Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism. Cortex 1992;28:231-239.
21. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmittor imbalance syndrome? Schizophr Bull 1990;16: 425-432.
22. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6:869-872.
23. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
24. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
25. White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anesthesiology 1982;56:119-136.
26. Schorn TOF, Whitwam JG. Are there long-term effects of ketamine on the central nervous system? Brit J Anesthesia 1980; 52:967-968.
27. Zsigmond EK, Domino EF. Clinical pharmacology of ketamine. In: Domino EF, ed. Status of ketamine in anesthesiology. Ann Arbor, MI: NPP Books, 1990:27-76.
28. Gole DJ, French J, Houser J, Domino EF. Plasma ketamine: relation to brain concentrations and the hippocampal electroencephalogram. In: Domino EF, ed. Status of ketamine in anesthesiology. Ann Arbor, MI: NPP Books, 1990:297-304.
29. Domino EF, Domino SE, Smith RE, et al. Ketamine kinetics in unmedicated and diazepam-premedicated subjects. Clin Pharmacol Ther 1984;36:645-653.
30. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186-197.
31. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24:1019-1025.
32. Corwin J, Snodgrass JG. Instructions for the Picture Memory Test. New York: Washington Square Associates, 1985.
33. Lezak DL. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press, 1995.
34. Van Kammen DP, Murphy DL. Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmocology (Berl) 1975;44:215-224.
35. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
36. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Operational Psychiatry 1980;11:48-64.
37. Como PG, and the Huntington Study Group. Internal validity and consistency of the Unified Huntington's Disease Rating Scale (UHDRS) [abstract]. Neurology 1995;45(suppl 4):A254.
38. Hariharan M, Murman DL, Foster NL. A new sensitive and simple HPLC method with U.V. detection for the analysis of ketamine and norketamine in human plasma. In: XVI International Congress of Clinical Chemistry. London: S. Karger, 1996:A249 (in press).
39. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
40. SAS Technical Report P-229, SAS/STAT Software: Changes and Enhancements, Release 6.07. Cary, NC: SAS Institute Inc., 1992:1-620.
41. Drachman DA. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974;30:113-121.
42. Petersen RC. Scopolamine induced learning failures in man. Psychopharmacology 1977;52:283-289.
43. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 1995; 20:250-267.
44. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990;11:81-86.
45. Kieburtz K, McDermott M, Marshall FJ, et al. Evidence of the glutamate antagonist remacemide hydrochloride in Huntington's disease [abstract]. Neurology 1995;45(suppl 4):A254.
46. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
47. Hirose K, Chan PH. Blockade of glutamate excitotoxicity and its clinical applications. Neurochem Res 1993;18:479-483.
48. Hartvig P, Valtysson J, Linder KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58:165-173.
49. Curran HV, Birch B. Differentiating the sedative, psychomotor, and amnestic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil. Psychopharmacology (Berl) 1991;103:519-523.
50. Cory-Slechta DA. The impact of NMDA receptor antagonists on learning and memory functions. Psychopharmacology Bull 1994;30:601-612.
51. Schmidt WJ. Behavioural effects of NMDA-receptor antagonists. J Neural Transm Suppl 1994;43:63-69.
52. Oye I, Hustveit O, Maurset A, et al. The chiral forms of ketamine as probes for NMDA receptor functions in humans. In: Kameyama T, Nabeshima T, Domino EF, eds. NMDA receptor related agents: biochemistry, pharmacology, and behavior. Ann Arbor, MI: NPP Books, 1991:381-389.
53. Walker JM, Bowen WD, Walder FO, et al. Sigma receptors: biology and function. Pharmacol Rev 1990;42:355-402.
54. Maurice T, Su TP, Parish DW, Nabeshima T, Privat A. Pre084, a σ selective PCP derivative attenuates MK-801-induced impairment of learning in mice. Pharmacol Biochem Behav 1994;49:859-869.
55. Clissold DB, Pontecorvo MJ, Jones BE, et al. NPC 16377, a potent and selective σ-ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 1993;265:876-886.
56. Leigh RJ, Newman SA, Folstein SE, et al. Abnormal ocular motor control in Huntington's disease. Neurology 1983;33: 1268-1275.
57. Collewijn H, Went LN, Tomminga EP, Vegter-Van der Vlis M. Oculomotor defects in patients with Huntington's disease and their offspring. J Neurol Sci 1988;86:307-320.
58. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.
59. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991;254:1515-1518.
60. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull 1994;30:533-540.
61. Farber NB, Price MT, Labruyere J, et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993;34:119-121.
62. Sharp FR, Butman M, Wang S, et al. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PC), MK801, and ketamine. J Neurosci Res 1992;33:605-616.